Physician profile
Stephanie Davidson
NPI 1508520321
$1,058.13
in general payments reported to CMS, 2019-2025
20 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.00 · 2022: $403 · 2023: $216 · 2024: $199 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.09 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $173.70 | 2022-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $83.50 | 2023-2024 | Brilinta, Farxiga |
| Scpharmaceuticals INC. | $64.26 | 2025 | |
| Viatris Specialty LLC | $36.74 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.34 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $24.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.73 | 2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $19.80 | 2022 | |
| Aimmune Therapeutics, INC. | $19.78 | 2023 | |
| Pfizer INC. | $19.28 | 2024 | |
| Almatica Pharma LLC | $16.83 | 2025 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $16.42 | 2024 | |
| Corcept Therapeutics | $16.08 | 2024 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.96 | 2021 | |
| Amgen INC. | $15.71 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.04 | 2025 | |
| Daiichi Sankyo INC. | $13.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.74 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.